Analytical methods for the quantification of ibandronate in body fluids and bone

被引:30
作者
Endele, R [1 ]
Loew, H [1 ]
Bauss, F [1 ]
机构
[1] Roche Diagnost GmbH, Pharma Res Penzberg, D-82377 Penzberg, Germany
关键词
quantification; derivatization; GC-MS; ELISA; ibandronate;
D O I
10.1016/j.jpba.2005.03.020
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The accurate determination of bisphosphonate levels in bone and biological fluids is important in both clinical and pharmacological/toxicological studies. Ibandronate is a potent nitrogen-containing bisphosphonate containing a tertiary amine group, which does not easily form chromophore derivatives that can be detected by UV light or fluorescence emissions. The current report describes the methodology and validation of a GC-MS assay for ibandronate in serum/plasma and urine, a similar, modified GC-MS method for measurement of bone ibandronate levels, and an ELISA for ibandronate determination in serum/plasma. The range of quantification for the GC-MS was 1-100 ng/ml and 2-7500 ng/ml in plasma or serum and urine, respectively, and 50-1600 pg/ml (potentially 10-320 pg/ml depending on sample size) for the ELISA in plasma or serum, These assays were comparable. The practical application of the assays in preclinical and clinical studies is briefly reviewed. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:246 / 256
页数:11
相关论文
共 43 条
[1]   Efficacy and safety of ibandronate given by intravenous injection once every 3 months [J].
Adami, S ;
Felsenberg, D ;
Christiansen, C ;
Robinson, J ;
Lorenc, RS ;
Mahoney, P ;
Coutant, K ;
Schimmer, RC ;
Delmas, R .
BONE, 2004, 34 (05) :881-889
[2]   Ibandronate: A clinical pharmacological and pharmacokinetic update [J].
Barrett, J ;
Worth, E ;
Bauss, F ;
Epstein, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :951-965
[3]  
Bauss F, 2002, J RHEUMATOL, V29, P990
[4]  
Bauss F, 2002, J RHEUMATOL, V29, P2200
[5]   Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing [J].
Bauss, F ;
Russell, RGG .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (06) :423-433
[6]   Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study [J].
Bergner, R ;
Dill, K ;
Boerner, D ;
Uppenkamp, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (07) :1281-1285
[7]   Bisphosphonates in the treatment of metastatic breast cancer [J].
Body, JJ .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) :477-485
[8]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[9]   Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].
Chen, TL ;
Berenson, J ;
Vescio, R ;
Swift, R ;
Gilchick, A ;
Goodin, S ;
LoRusso, P ;
Ma, PM ;
Ravera, C ;
Deckert, F ;
Schran, H ;
Seaman, J ;
Skerjanec, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236
[10]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249